Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 8;15:331–343. doi: 10.2147/OTT.S357326

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Hui et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Antitumor activity of DP303c in vivo. (A) Effect of in vivo antitumor activity on NCI-N87 xenograft model. DP303c was administered intravenously as a single dose of 2.5, 5 or 10 mg/kg on day 0. DP001 (10 mg/kg) was injected intravenously on days 0. T-DM1 (10 mg/kg) was given through intravenous administration on day 0. (B) In antitumor activity effect on HCC1954 xenograft model. The effects of DP303c (3, 10 or 15 mg/kg), DP001 (15 mg/kg), and T-DM1 at 15 mg/kg were evaluated. After randomized grouping, the mice in each group were administered drugs on days 0 and 7. (C) In vivo tumor inhibition effect on SK-OV-3 xenograft model. Different doses (1, 3 or 10 mg/kg) of DP303c were given via intravenous injection at (mention days). DP001 (10 mg/kg) and T-DM1 (10 mg/kg) were injected intravenously. After randomized grouping, the mice in each group were administered drugs on days 0 and 7. (D) In vivo antitumor efficacy on JIMT-1 xenograft model. The effects of DP303c (0.3, 1, 3 or 10 mg/kg), DP001 (10 mg/kg), and T-DM1 (10mg/kg) were also evaluated as a single intravenous injection on day 0. Each point indicates the tumor volume, which was represented as the average tumor volume ± SD (n = 9).